Back to Search
Start Over
Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer
- Source :
- Expert Review of Clinical Pharmacology. 9:69-79
- Publication Year :
- 2015
- Publisher :
- Informa UK Limited, 2015.
-
Abstract
- Cabozantinib (XL-184) is a potent inhibitor of MET, VEGFR 2/KDR, RET and other receptor tyrosine kinases, such as KIT, AXL and FLT3. Its efficacy against MTC has been demonstrated in a prospective, randomized, placebo-controlled study (EXAM). Cabozantinib comparing to placebo significantly prolonged progression free survival both in hereditary and sporadic MTC, 11.2 vs 4.0 months, respectively. Final analysis showed no global differences in overall survival (OS) between cabozantinib and placebo. However, in a subgroup with RET M918T mutation the difference in OS was significant: 44.3 vs 18.9 months, respectively. Among the most frequent cabozantinib-related adverse events (AEs), observed in >30% of patients were diarrhea, palmar-plantar erythrodysesthesia, decreased weight, decreased appetite, nausea, fatigue, dysgeusia, hair color changes and hypertension. Expert Commentary: Cabozantinib constitutes an effective treatment option with acceptable toxicity in MTC patients showing either germinal or sporadic tumor RET M918T mutation as the drug prolonged OS in these subjects.
- Subjects :
- Oncology
medicine.medical_specialty
Pathology
Cabozantinib
Pyridines
Nausea
Antineoplastic Agents
030209 endocrinology & metabolism
Placebo
Disease-Free Survival
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
Animals
Humans
Medicine
Anilides
Pharmacology (medical)
Thyroid Neoplasms
Progression-free survival
Neoplasm Metastasis
General Pharmacology, Toxicology and Pharmaceutics
Adverse effect
Protein Kinase Inhibitors
business.industry
Proto-Oncogene Proteins c-ret
Medullary thyroid cancer
General Medicine
medicine.disease
Carcinoma, Neuroendocrine
Dysgeusia
Survival Rate
chemistry
030220 oncology & carcinogenesis
Mutation
Toxicity
Disease Progression
medicine.symptom
business
Subjects
Details
- ISSN :
- 17512441 and 17512433
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Expert Review of Clinical Pharmacology
- Accession number :
- edsair.doi.dedup.....f9b021c376aee76e6b342144bf71f592